PE-22-28
- Category
- Brain & Cognition
- Regulatory status
- Not FDA-approved
What it is
A spadin-derived peptide marketed for rapid antidepressant effects by blocking brain TREK-1 channels, giving a ketamine-like mood lift via a different pathway. Evidence is preclinical, from rodent studies, with no human trials and speculative cognitive claims. The headline gap is safety: no human safety data exists, and cell-proliferation and SSRI/SNRI concerns are unresolved. It has no approved use and is sold only as an unregulated research chemical.
Read Full recordStudied uses & evidence
Studied uses(6)
Rapid-onset antidepressant activity
MediumConsistent rodent antidepressant-like effects with a clear mechanism, but no human trials yet.
Enhanced hippocampal neurogenesis
MediumTwo independent rodent studies show increased neurogenesis markers, not yet tested in humans.
Increased synaptogenesis and synaptic plasticity
MediumRodent and cell studies show increased synaptic protein markers, with no human data yet.
Evidence limits
- Evidence Level
- Preclinical Only
All evidence for PE-22-28 comes from in vitro cell-based assays (patch-clamp electrophysiology on hTREK-1/HEK cells, cortical neuron cultures) and in vivo mouse behavioral models (forced swimming test, tail suspension test, novelty suppressed feeding test). No human clinical trials (Phase 1, 2, or 3) have been published or registered on ClinicalTrials.gov as of March 2026. The broader spadin research program (from which PE-22-28 derives) spans approximately 20 PubMed-indexed publications from 2006-2020 across multiple independent research groups at CNRS/IPMC. The preclinical evidence is consistent: PE-22-28 and spadin show robust TREK-1 inhibition, rapid antidepressant effects, neurogenesis promotion, synaptogenesis enhancement, and BDNF upregulation without cardiac or other systemic side effects. However, the absence of any human data means efficacy, pharmacokinetics, and safety in humans remain entirely unestablished. French patent FR3057266A1 covers PE-22-28 and analogs for depression treatment, indicating commercial development intent.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Concurrent serotonergic medications (SSRIs, SNRIs, MAOIs)
HighTREK-1 channel blockade has antidepressant effects. Combined with serotonergic drugs, risk of excessive monoamine activity.
Cardiac arrhythmias
ModerateTREK-1 channels are expressed in cardiac tissue. Preclinical data shows no cardiac effects but human data lacking.
General cautions
Pregnancy
AbsoluteNo human data. Entirely preclinical — TREK-1 channels play roles in neurodevelopment.
Risk summary(5)
Risks = level of concern: High · Moderate · Low · Theoretical
No established human safety profile
HighTheoretical serotonin syndrome risk with SSRIs/SNRIs
TheoreticalPotential for uncontrolled neurogenesis or cellular proliferation
TheoreticalTREK-1 inhibition and neuroprotection trade-off
LowQuality and purity concerns: unregulated products sold online vary in purity
High
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.